REG - Hutchmed China Ltd - Vesting of awards under the LTIP
21/10/2024 09:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241021:nRSU9386Ia&default-theme=true
RNS Number : 9386I Hutchmed (China) Limited 21 October 2024
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Monday, October 21, 2024:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards
granted under the Long Term Incentive Plan ("LTIP") on October 20, 2021 to the
following persons discharging managerial responsibilities were vested on
October 20, 2024:-
Award Holder Number of American depositary shares ("ADS")
Dr Dan Eldar (Non-executive Director ("NED")) 1,938
Ms Edith Shih (NED) 1,938 ((1))
Mr Paul Carter (Independent Non-executive Director ("INED")) 1,647 ((2))
Mr Graeme Jack (INED) 1,938
Professor Tony Mok (INED) 1,938
Notes:
(1) These ADSs were not received by Ms Edith Shih, but were received by or
for the account of her employer, Hutchison International Limited.
(2) Mr Paul Carter elected, on acceptance of the grant of his awards, to
have 15% of his LTIP awards (amounting to US$9,375 with respect to his awards
which vested on October 20, 2024) held on his behalf by the trustee
administering the LTIP pending vesting in the form of cash, to settle his tax
liabilities in respect of his awards.
(3) Since the vesting date is not a trading day, the relevant ADSs are
scheduled to be transferred to the award holders on October 21, 2024.
The notifications set out below are provided in accordance with the
requirements of the UK Market Abuse Regulation.
(a) Dr Dan Eldar
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Dr Dan Eldar
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 1,938 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2024-10-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2024-10-20
f)
Place of the transaction
Outside a trading venue
(b) Mr Paul Carter
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Mr Paul Carter
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 1,647 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2024-10-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2024-10-20
f)
Place of the transaction
Outside a trading venue
(c) Mr Graeme Jack
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Mr Graeme Jack
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 1,938 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2024-10-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2024-10-20
f)
Place of the transaction
Outside a trading venue
(d) Professor Tony Mok
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Professor Tony Mok
2 Reason for the notification
a) Position/status Independent Non-Executive Director
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument ADS each representing five Ordinary Shares of US$0.10
Identification code
ADS ISIN: US44842L1035
b) Nature of the transaction Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 1,938 ADS
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2024-10-20
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2024-10-20
f)
Place of the transaction
Outside a trading venue
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three medicines marketed in China, the first of which is
also marketed in the US and Europe. For more information, please visit:
www.hutch-med.com (http://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .
CONTACTS
Investor Enquiries +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)
Media Enquiries
Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
FTI Consulting (mailto:HUTCHMED@fticonsulting.com)
Zhou Yi, Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
(mailto:HUTCHMED@brunswickgroup.com)
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Liberum +44 (20) 7886 2500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHMBBRTMTBTMTIRecent news on HUTCHMED (China)
See all newsRCS - Hutchmed China Ltd - HUTCHMED - Data to be Presented at AACR 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase II Study
AnnouncementREG - Hutchmed China Ltd - 2024 Annual Report and Notice of AGM
AnnouncementREG - Hutchmed China Ltd - Extraordinary General Meeting – Poll Results
AnnouncementRCS - Hutchmed China Ltd - NMPA Conditional Approval for TAZVERIK®
Announcement